Concepts in radiotherapy and immunotherapy: Anti-CD20 mechanisms of action and targets
- 28 February 2005
- journal article
- Published by Elsevier in Seminars in Oncology
- Vol. 32, 19-26
- https://doi.org/10.1053/j.seminoncol.2005.01.010
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Rituximab: Mechanism of action and resistanceSeminars in Oncology, 2002
- Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-TreatmentJournal of Clinical Oncology, 2000
- Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysisBlood, 2000
- Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 1999
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- Mice carrying a CD20 gene disruptionImmunogenetics, 1998
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaBlood, 1997
- Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphomaBiochemical Society Transactions, 1997
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994
- Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemiaAmerican Journal of Hematology, 1992